Vaxcyte, Inc. Common Stock (PCVX) Financials
Key financial figures for Vaxcyte, Inc. Common Stock (Q3 2026).
Vaxcyte reported a Q3 2026 net loss of $297.1 million and said VAX-31 met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 adult trial, with a BLA now planned for the first half of 2028. Net loss was $297.1M ($1.99 per share) versus $212.8M ($1.56 per share) in Q3 2025; the company has no product revenue. R&D expense was $270.3M versus $209.9M a year earlier, driven by PCV program development and manufacturing costs (including commercial-launch preparation) and OPUS Phase 3 trial expenses; G&A was $37.9M versus $32.4M. Figures are for Q3 2026, as Vaxcyte Inc. reported them.
- Revenue
- $0
- Net Income
- -$297M
- EPS
- $-1.99
- Total Assets
- $3.0B
- Operating Cash Flow
- -$224M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$297M | -$1.99 | -$229M | |
| Q2 FY2026 | $0 | -$284M | -$1.97 | -$532M | |
| Q1 FY2026 | $0 | -$321M | -$2.30 | -$295M | |
| Q4 FY2025 | $0 | -$247M | -$1.81 | ||
| Q3 FY2025 | $0 | -$213M | -$1.56 | -$155M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$767M | -$5.63 | -$669M | |
| FY2024 | $0 | -$464M | -$3.80 | -$475M | |
| FY2023 | $0 | -$402M | -$4.14 | -$365M |
Frequently asked questions
What was Vaxcyte Inc.'s revenue last quarter?
Vaxcyte Inc. reported revenue of $0.00 for Q3 FY2026.
Is Vaxcyte Inc. profitable?
Not in its most recent reported period. Vaxcyte Inc. reported a net loss of $297.1 million for Q3 FY2026.
How much free cash flow did Vaxcyte Inc. generate?
Vaxcyte Inc. generated free cash flow of -$229.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Vaxcyte, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.